BioNTech SE (NASDAQ:BNTX) Shares Bought by Midwest Professional Planners LTD.

Midwest Professional Planners LTD. raised its stake in BioNTech SE (NASDAQ:BNTX) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,051 shares of the company’s stock after acquiring an additional 222 shares during the period. Midwest Professional Planners LTD.’s holdings in BioNTech were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of BNTX. FMR LLC boosted its stake in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the third quarter worth about $59,485,000. Braidwell LP acquired a new stake in shares of BioNTech during the third quarter worth about $29,425,000. abrdn plc boosted its stake in shares of BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after buying an additional 159,676 shares during the period. Finally, Redmile Group LLC acquired a new stake in shares of BioNTech during the third quarter worth about $18,345,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Up 2.1 %

Shares of BioNTech stock opened at $99.47 on Friday. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $23.85 billion, a PE ratio of -47.37 and a beta of 0.30. The company has a 50-day moving average of $115.49 and a two-hundred day moving average of $113.01.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. During the same period last year, the company posted $1.90 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, research analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

BNTX has been the subject of several recent research reports. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Citigroup initiated coverage on shares of BioNTech in a research note on Thursday. They set a “buy” rating and a $145.00 target price for the company. Wells Fargo & Company initiated coverage on shares of BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. Finally, BMO Capital Markets increased their target price on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $143.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.